Eton Pharmaceuticals (ETON) announced the submission of a NDA to the U.S. FDA for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals management to meet virtually with B. Riley
- Eton Pharmaceuticals management to meet with Craig Hallum
- Eton Pharmaceuticals out-licenses international rights to Increlex
- Eton Pharmaceuticals price target raised to $24 from $21 at B. Riley
- Eton Pharmaceuticals price target raised to $26 from $23 at Craig-Hallum